Galan Lithium hikes its lithium resource by 2.5x and shareholders reward it
Nick Sundich, October 25, 2022
Galan Lithium (ASX:GLN) became the latest lithium explorer to unveil an upgraded JORC Resource. But it has been a while since we saw a resource upgrade that was 2.5x higher. And shareholders are excited.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Galan Lithium has an upgraded resource
Galan Lithium has the Hombre Muerto West Project (HMW) in Argentina. Since making an initial Resource Estimate in early 2020, it has done further exploration work at the project with success. And today it capped off the hard work by unveiling a new Mineral Resource Estimate accounting for its success.
HMW now has a resource of 5.8Mt contained lithium carbonate equivalent (LCE) at 866mg/l lithium. The total Galan Lithium Resource (including its Candelas project that also lies in Argentina) is 6.5Mt at 839mg/l lithium.
So, what is next?
Although Galan Lithium shares are down this year, they have gained ~20% this morning. Shareholders are excited not just about the resource but about the upcoming DFS in the next quarter. And with the booming demand for lithium, investor appetite for the sector is following suit.
Galan Lithium (ASX:GLN) share price chart (Graph: TradingView)
However, we think shareholders should be cautious about the economics of the project. It is located inland, 1400km from Buenos Aires, and is in a high region of the Andes at 4,000m above sea-level. Ultimately, shareholders may not have to worry about this until the Bankable Feasibility Study phase, and for now can just look forward to the DFS.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Telix Pharmaceuticals (ASX:TLX): It’s made ~A$1.7bn in revenue from Illucix, but here’s why the best is yet to come!
What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful…
Anti Woke ETFs: Do they practice what they preach and have they outperformed since Trump’s return to power?
Have you ever heard of so-called ‘Anti Woke ETFs’? If you’re sick of companies that are big on ESG, this…
Trump’s Tariffs Are Back in the News—What’s the Impact on Global Supply Chains?
In recent months, the conversation around trade tariffs has re-emerged, with former President Donald Trump’s trade policies making headlines once…